Congratulations to our team members, Kristine Ashcraft, Burns C. Blaxall, PhD, FACC, FAHA, FISHR, FAPS, and Houda Hachad, recipients of STRIPE's 2024 Annual Double Helix Award! #PGx #pharmacogenomics #STRIPEcc
Aranscia
Hospitals and Health Care
Houston, Texas 595 followers
Empowering human-first diagnostic solutions
About us
Aranscia unlocks the power of precision medicine by serving the needs of clinical professionals directly within the care workflow.
- Website
-
www.aranscia.com
External link for Aranscia
- Industry
- Hospitals and Health Care
- Company size
- 51-200 employees
- Headquarters
- Houston, Texas
- Type
- Privately Held
Locations
-
Primary
Houston, Texas, US
Employees at Aranscia
Updates
-
Burns C. Blaxall, PhD, FACC, FAHA, FISHR, FAPS, Senior Vice President of Precision Medicine at Aranscia, will be joining the upcoming STRIPE conference as a moderator for the Study Design Considerations Consensus Workshop. Join Burns and the STRIPE community, register here: https://lnkd.in/eiZfrSsQ #BurnsBlaxall #STRIPEcc
Join us for the STRIPE Annual Meeting and PGx Consensus Workshop! October 23-25, 2024 | U.S. Pharmacopeia Campus, Rockville, MD We’re excited to introduce our lineup of speakers for this year's event. Each week, we’ll highlight experts who will be sharing their insights on pharmacogenomics. Today, we are thrilled to feature Burns C. Blaxall, PhD, FACC, FAHA, FISHR, FAPS, Senior Vice President, Precision Medicine, Aranscia. Dr. Blaxall will moderate the Study Design Considerations Consensus Workshop. For more information and to register, visit https://lnkd.in/eiZfrSsQ. We look forward to seeing you there! #PGx #pharmacogenomics #STRIPEcc
-
"PGx testing in mental health has been demonstrated to shorten the time to remission, reduce pharmacy costs, and decrease psychiatric hospital stays." - Kristine Ashcraft, President and Founder of YouScript, an Aranscia company, in HIT Consultant Media. When typical mental health treatments often involve trial and error prescribing, the time to treatment can be detrimental. #PGx testing before prescribing can help get the patient or resident on the correct medication sooner, saving time, money, and lives. #WorldMentalHealthDay #BeStigmaFree #StopTheStigma #MentalHealthAwareness
-
In honor of Mental Illness Awareness Week, our team at Aranscia wants to take a moment to highlight the importance of #pharmacogenomics when it comes to mental health. Mental disorders, ranging from anxiety to depression to schizophrenia and PTSD, are incredibly common, yet often not discussed. A simple #PGx test can help reduce trial-and-error prescribing. Learn more about Mental Illness Awareness Week from NAMI at nami.org/MIAW #MentalIllnessAwarenessWeek #NAMIStigmaFree #StigmaFree
-
Join Burns C. Blaxall, PhD, FACC, FAHA, FISHR, FAPS, Aranscia SVP, Precision Medicine, for an exploratory discussion regarding AI in the healthcare space. Burns will speak alongside other industry experts, including: - Gabriele Allegri, Vice President of Global Precision Medicine, Johnson & Johnson Innovative Medicine - Christina Kotsi, Director of Medical Digital Strategy for Global Medical Affairs in Oncology at Bayer - Lee-Anne Zinetti, Executive Director of Healthcare Systems and Diagnostics Oncology at Novartis
At the 2024 Precision Health Summit, the session "Precision Medicine: How AI is Reshaping Medicine", scheduled for October 9 from 4:00 pm to 4:45 pm at One World Trade Center, will explore how artificial intelligence (AI) is transforming healthcare. As AI becomes integral to precision medicine, its role in enhancing patient care is undeniable. Gabriele Allegri Vice President of Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine, will discuss how AI-driven analytics are enabling personalized treatment strategies for complex diseases. Christina Kotsi, Director of Medical Digital Strategy for Global Medical Affairs in Oncology at Bayer, will highlight AI’s role in revolutionizing oncology through digital transformation. Burns C. Blaxall, Senior Vice President of Precision Medicine at Aranscia, will focus on AI-powered diagnostics that enhance clinical decision-making. Lee-Anne Zinetti, Executive Director of Healthcare Systems and Diagnostics Oncology at Novartis, will share how AI is reshaping oncology care by improving access to personalized treatments. This session will highlight how AI is defining a new era in medicine, characterized by precision, efficiency, and personalized care, offering a key look at the future of healthcare. #precisionhealth #personalizedmedicine #healthtech #healthandai Nabiha Saklayen Matthias Wagner Ali Mostashari, Raya Khanin Fern Lazar Martin Alexander Gershon, Joshua Di Frances Gabriele Allegri Christina Kotsi Lee-Anne Zinetti Steve Evans Leon Eisen, Gil Bashe Asieh Golozar Aquil Harjivan Parastoo Khoshakhlagh, Arda Ural, Pooja Majmudar, Allan Gobbs Burns C. Blaxall, Glenn Tyranski Henning Stein, Matt Posta
-
Aranscia's Houda Hachad commented on her recent co-authored paper released in The Journal of Molecular Diagnostics, "I am honored that I had the opportunity to serve on this amazing panel! We all gathered as representatives of our diverse international PGx community - from consortia leaders, molecular testing experts, and PGx implementers to streamline DPYD testing for all populations. Our joint consensus recommendation, including an expanded list of variants reported in diverse populations across the globe, is available to all – Let’s put it to use! It is time to follow the steps of great implementers of preemptive DPYD testing, such as Atrium Health (read here: https://lnkd.in/gGu7U6dY), and others, and prevent unnecessary harm and hospitalizations." To read the full paper in JMD Journal, click here: https://lnkd.in/dTxiqyNd
DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmac
jmdjournal.org
-
Congratulations to #California - as of 7/1/24, #pharmacgenomics testing is now covered by Medi-Cal and commercial insurance!
As of today, evidence-based #pharmacogenomics testing is now covered by Medi-Cal (AB425) and commercial insurers (SB496) in the state of #California, aligning with Medicare coverage in place since 2020. After years of work, I want to stop and celebrate this win that will help curb the annual loss of 33,000 lives and 62 billion dollar spend due to non-optimized medications in the state. This would not have happened without the leadership of Assemblymember Alvarez, the tireless efforts of his legislative assistant Cynthia Yepez, and countless meetings with other California legislators coordinated by Chantelle Schenning, PhD, MHA, Megan Boyd, MA, CAPM and Michael Hawkins. This would not have happened without outreach to Alvarez by a brave young girl and her Mother looking to improve access for others when #pgx testing resulted in resolution of her #depression symptoms after numerous failed medications. This would not have happened without live testimony from Christine Von Raesfeld 💜on the impact pharmacogenomic testing had in improving her quality of life or Bani Tamraz, Pharm.D., Ph.D. on the science and clinical and financial benefits of testing. This would not have happened without companies and individuals reaching out to their legislators to voice their support for the legislation. I am grateful that so many more patients can now access personalized care, but the work is not over until similar efforts move forward in every state and nationally. Please see where your state stands in moving biomarker legislation forward and join the efforts if needed - https://lnkd.in/gwgcHA8Q. And support national efforts to reduce adverse drug events by asking your Congressional representatives to support the Right Drug Dose Now Act of 2024 - https://lnkd.in/dAf--N7p.
-
We are excited to announce our innovative partnership with Signature RX to develop novel biomarkers and personalized medication management solutions for the effective use of GLP-1 medications. Read the full press release to learn more about this multi-phase partnership and how the program aims to bring a comprehensive, personalized approach to GLP-1s: https://lnkd.in/gVj647wQ #ObesityMedicine #GLP1 #PrecisionMedicine #NovelBiomarkers #WeightLossMedicine #DiabetesMedicine
Aranscia and Signature RX Announce Personalized Medication Management Program for GLP-1s
aranscia.com
-
In honor of Women's Health Week, our team at Aranscia wants to take a moment to highlight the importance of #pharmacogenomics when it comes to women's health. Adverse drug events are nearly twice as common for women as they are for men. A simple #PGx test can help reduce that number. #WomensHealthWeek #WomensHealthWeek2024 #adversedrugevents #adversedrugreactions #precisionmedicine #precisiondosing
-
Join our team at Aranscia and celebrate National DNA Day! #NationalDNADay celebrates significant scientific milestones that have unraveled the mystery of what makes us who we are. Learn more about the history of National DNA Day and the National Human Genome Research Institute (NHGRI)'s goal to continue to spread awareness of genetics and genomics to teachers, students, and the public nationwide. #DNADay24 #Genomics #Genetics